Assessment of ascites

References

Key articles

Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021 Aug;74(2):1014-48.Full text  Abstract

Menon KV, Shah V, Kamath PS. The Budd-Chiari syndrome. N Engl J Med. 2004 Feb 5;350(6):578-85. Abstract

Reference articles

1. Krige JEJ, Beckingham IJ. Clinical review: ABC of disease of liver, pancreas and biliary system. Portal hypertension-2. Ascites, encephalopathy and other conditions. BMJ. 2001 Feb 17;322(7283):416-8.Full text  Abstract

2. GBD 2017 Cirrhosis Collaborators. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020 Mar;5(3):245-66.Full text  Abstract

3. Ginès P, Cardenas A., Arroyo V, et al. Management of cirrhosis and ascites. N Engl J Med. 2004 Apr 15;350(16):1646-54. Abstract

4. Sikuler E, Ackerman Z, Braun M, et al. Guidelines for diagnosis and management of cirrhotic ascites and its complications. The Israeli Association for the Study of the Liver [in Hebrew]. Harefuah. 2012 Dec;151(12):705-8. Abstract

5. Royal College of Obstetricians and Gynaecologists. Management of ascites in ovarian cancer patients. Nov 2014 [internet publication].Full text

6. Elkassem S, Dixon E, Conly J, et al. Primary peritonitis in a young healthy woman: an unusual case. Can J Surg. 2008 Apr;51(2):E40-1.Full text  Abstract

7. Runyon BA, Montano AA, Akriviadis EA, et al. The serum-ascites albumin gradient is superior to the exudate-transudate concept in the differential diagnosis of ascites. Ann Intern Med. 1992 Aug 1;117(3):215-20. Abstract

8. Ge PS, Runyon BA. Treatment of patients with cirrhosis. N Engl J Med. 2016 Aug 25;375(8):767-77. Abstract

9. Zhai M, Liu Z, Long J, et al. The incidence trends of liver cirrhosis caused by nonalcoholic steatohepatitis via the GBD study 2017. Sci Rep. 2021 Mar 4;11(1):5195.Full text  Abstract

10. Ricart E, Soriano G, Novella MT, et al. Amoxicillin-clavulanic acid versus cefotaxime in the therapy of bacterial infections in cirrhotic patients. J Hepatol. 2000 Apr;32(4):596-602. Abstract

11. Felisart J, Rimola A, Arroyo V, et al. Cefotaxime is more effective than is ampicillin-tobramycin in cirrhotics with severe infections. Hepatology. 1985 May-Jun;5(3):457-62. Abstract

12. Chen TA, Lo GH, Lai KH, et al. Single daily amikacin versus cefotaxime in the short-course treatment of spontaneous bacterial peritonitis in cirrhotics. World J Gastroenterol. 2005 Nov 21;11(43):6823-7.Full text  Abstract

13. Angeli P, Guarda S, Fasolato S, et al. Switch therapy with ciprofloxacin vs. intravenous ceftazidime in the treatment of spontaneous bacterial peritonitis in patients with cirrhosis: similar efficacy at lower cost. Aliment Pharmacol Ther. 2006 Jan 1;23(1):75-84.Full text  Abstract

14. Strauss E, Caly WR. Spontaneous bacterial peritonitis: a therapeutic update. Expert Rev Anti Infect Ther. 2006 Apr;4(2):249-60. Abstract

15. Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021 Aug;74(2):1014-48.Full text  Abstract

16. Aithal GP, Palaniyappan N, China L, et al. Guidelines on the management of ascites in cirrhosis. Gut. 2021 Jan;70(1):9-29.Full text  Abstract

17. Akriviadis EA. Hemoperitoneum in patients with ascites. Am J Gastroenterol. 1997 Apr;92(4):567-75. Abstract

18. Tapping CR, Ling L, Razack A. PleurX drain use in the management of malignant ascites: safety, complications, long-term patency and factors predictive of success. Br J Radiol. 2012 May;85(1013):623-8.Full text  Abstract

19. Martin LG. Percutaneous placement and management of the Denver shunt for portal hypertensive ascites. AJR Am J Roentgenol. 2012 Oct;199(4):W449-53.Full text  Abstract

20. Israelsen M, Krag A, Allegretti AS, et al. Terlipressin versus other vasoactive drugs for hepatorenal syndrome. Cochrane Database Syst Rev. 2017 Sep 27;(9):CD011532.Full text  Abstract

21. Sanyal AJ, Boyer T, Garcia-Tsao G, et al. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology. 2008 May;134(5):1360-8.Full text  Abstract

22. European Association for the Study of the Liver. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018 Aug;69(2):406-60.Full text  Abstract

23. Kim WR, Brown RS Jr, Terrault NA, et al. Burden of liver disease in the United States: summary of a workshop. Hepatology. 2002 Jul;36(1):227-42. Abstract

24. Blachier M, Leleu H, Peck-Radosavljevic M, et al. The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol. 2013 Mar;58(3):593-608. Abstract

25. Cattau E, Benjamin SB, Knuff TE, et al. The accuracy of the physical exam in the diagnosis of suspected ascites. JAMA. 1982 Feb 26;247(8):1164-6. Abstract

26. Light, RW. Clinical practice. Pleural effusion. N Engl J Med. 2002 Jun 20;346(25):1971-7. Abstract

27. Inadomi J, Cello JP, Koch J. Ultrasonographic determination of ascitic fluid. Hepatology. 1996 Sep;24(3):549-51. Abstract

28. Moore KP, Wong F, Gines P, et al. The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology. 2003 Jul;38(1):258-66. Abstract

29. Krige JE, Beckingham IJ. Clinical review: ABC diseases of liver, pancreas and biliary system. Portal hypertension - 1: varices. BMJ. 2001 Feb 10;322(7282):348-51.Full text  Abstract

30. Sakai H, Sheer TA, Mendler MH, et al. Choosing the location for non-image guided abdominal paracentesis. Liver Int. 2005 Oct;25(5):984-6. Abstract

31. Pache I, Bilodeau M. Severe haemorrhage following abdominal paracentesis for ascites in patients with liver disease. Aliment Pharmacol Ther. 2005 Mar 1;21(5):525-9.Full text  Abstract

32. Runyon BA. Paracentesis of ascitic fluid. A safe procedure. Arch Intern Med. 1986 Nov;146(11):2259-61. Abstract

33. McVay PA, Toy PT. Lack of increased bleeding after paracentesis and thoracentesis in patients with mild coagulation abnormalities. Transfusion. 1991 Feb;31(2):164-71. Abstract

34. European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol. 2010;53(3):397-417.Full text  Abstract

35. Aithal GP, Palaniyappan N, China L, et al. Guidelines on the management of ascites in cirrhosis. Gut. 2021 Jan;70(1):9-29.Full text  Abstract

36. Wong CL, Holroyd-Leduc J, Thorpe KE, et al. Does this patient have bacterial peritonitis or portal hypertension? How do I perform a paracentesis and analyze the results? JAMA. 2008 Mar 12;299(10):1166-78.Full text  Abstract

37. Rimola A, Garcia-Tsao G, Navasa M, et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club. J Hepatol. 2000;32(1):142-53. Abstract

38. Bernardi M, Carceni P, Navickis RJ, et al. Albumin infusion in patients undergoing large-volume paracentesis: a meta-analysis of randomized trials. Hepatology. 2012 Apr;55(4):1172-81.Full text  Abstract

39. Garcia-Tsao G, Abraldes JG, Berzigotti A, et al. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology. 2017 Jan;65(1):310-35. Abstract

40. Walsh K, Alexander G. Alcoholic liver disease. Postgrad Med J. 2000 May;76(895):280-6.Full text  Abstract

41. Runyon BA. Cardiac ascites: a characterization. J Clin Gastroenterol. 1988 Aug;10(4):410-2. Abstract

42. Orth SR. Ritz E. The nephrotic syndrome. N Engl J Med. 1998 Apr 23;338(17):1202-11. Abstract

43. Tenner S, Baillie J, DeWitt J, et al. American College of Gastroenterology guideline: management of acute pancreatitis. Am J Gastroenterol. 2013 Sep;108(9):1400-15; 1416. Abstract

44. American Society for Clinical Pathology. Do not test for amylase in cases of suspected acute pancreatitis. Instead, test for lipase. 14 Sep 2016 [internet publication].Full text

45. Rompianesi G, Hann A, Komolafe O, et al. Serum amylase and lipase and urinary trypsinogen and amylase for diagnosis of acute pancreatitis. Cochrane Database Syst Rev. 2017 Apr 21;(4):CD012010.Full text  Abstract

46. Aggarwal R, Ranjan P. Clinical review: preventing and treating hepatitis B infection. BMJ. 2004 Nov 6;329(7474):1080-6.Full text  Abstract

47. Kaplan MM, Gershwin ME. Primary biliary cirrhosis. N Engl J Med. 2005 Sep 22;353(12):1261-73. Abstract

48. Lindor KD, Bowlus CL, Boyer J, et al. Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2019 Jan;69(1):394-419. Abstract

49. Ryder SD, Beckingham IJ. ABC of diseases of liver pancreas and biliary system. Other causes of parenchymal liver disease. BMJ. 2001 Feb 3;322(7281):290-2.Full text  Abstract

50. Pietrangelo A. Hereditary hemochromatosis: a new look at an old disease. N Engl J Med. 2004 Jun 3;350(23):2383-97. Abstract

51. Ryan A, Nevitt SJ, Tuohy O, et al. Biomarkers for diagnosis of Wilson's disease. Cochrane Database Syst Rev. 2019 Nov 19;2019(11):CD012267.Full text  Abstract

52. Nishimura RA. Constrictive pericarditis in the modern era: a diagnostic dilemma. Heart. 2001 Dec;86(6):619-23.Full text  Abstract

53. Osterberg L, Vagelos R, Atwood JE. Case presentation and review: constrictive pericarditis. West J Med. 1998 Oct;169(4):232-9.Full text  Abstract

54. Oren RM, Grover-McKay M, Stanford W, et al. Accurate preoperative diagnosis of pericardial constriction using cine computed tomography. J Am Coll Cardiol. 1993 Sep;22(3):832-8.Full text  Abstract

55. Menon KV, Shah V, Kamath PS. The Budd-Chiari syndrome. N Engl J Med. 2004 Feb 5;350(6):578-85. Abstract

56. Wood ML, Foulds IS, French MA. Protein losing enteropathy due to systemic lupus erythematosus. Gut. 1984 Sep;25(9):1013-5.Full text  Abstract

57. Harmon RL, Sugarbaker PH. Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer. Int Semin Surg Oncol. 2005 Feb 8;2(1):3.Full text  Abstract

58. Turlakow A, Yeung HW, Salmon AS, et al. Peritoneal carcinomatosis: role of 18F-FDG PET. J Nucl Med. 2003 Sep;44(9):1407-12.Full text  Abstract

59. Ross AG, Bartley PB, Sleigh AC, et al. Schistosomiasis. N Engl J Med. 2002 Apr 18;346(16):1212-20. Abstract

60. Mills JA. Systemic lupus erythematosus. N Engl J Med. 1994 Jun 30;330(26):1871-9. Abstract

61. Lewis M, Howdle PD. The neurology of liver failure. QJM. 2003 Sep;96(9):623-33. Abstract

62. Wittmann DH, Schein M, Condon RE. Management of secondary peritonitis. Ann Surg. 1996 Jul;224(1):10-8.Full text  Abstract

63. al Karawi MA, Mohamed AE, Yasawy MI, et al. Protean manifestation of gastrointestinal tuberculosis: report on 130 patients. J Clin Gastroenterol. 1995 Apr;20(3):225-32. Abstract

64. Ravdin IS, Morrison ME, Smyth CM. Bile peritonitis and bile ascites. Ann Surg. 1929 Jun;89(6):867-77.Full text  Abstract

Use of this content is subject to our disclaimer